Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Ono Pharmaceutical Co., Ltd.

小野薬品工業株式会社は、日本の製薬会社で、医薬品の研究開発、製造、販売を行っている。

Metric
Company Name	Ono Pharmaceutical Co., Ltd.
Symbol	4.53K
MSH ID	COM:ONO-PHARMA
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - General
Country	JP
Stage
Employee Count	3.85K
Website	ono-pharma.com
LinkedIn
Founders

Metric
Market Cap	6.99B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	3.35B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.50B
EBITDA	1.21B
Operating Income	1.09B
Net Income	853.52M
EPS	1.78
Diluted EPS	1.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.76
Operating Profit Margin	0.33
EBITDA Margin	0.36
Net Profit Margin	0.26
Return on Equity	0.17
Return on Assets	0.14
Return on Capital Employed	0.20

COM:ONO-PHARMA

小野薬品工業株式会社

Last Close

1,747.50

25/11 06:45

Market Cap

1.05T

Beta: -

Volume Today

4.63M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	9.93
P/B Ratio	1.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.41
EV Multiple	6.94

Metric
Days Sales Outstanding	105.70
Days Payables Outstanding	159.64
Days Inventory Outstanding	153.59
Operating Cycle	263.27
Cash Conversion Cycle	90.21
Asset Turnover	0.56

Metric
Operating Cash Flow	738.03M
Free Cash Flow	599.11M
Cash Flow to Debt	12.49
Operating Cash Flow/Sales	0.24
Free Cash Flow Yield	0.08

Metric
Cash & Equivalents	1.11B
Accounts Receivable	-131.93M
Inventory	324.32M
Goodwill
Debt to Capitalization	0.16
Debt to Assets	0.01
Current Ratio	3.52
Quick Ratio	3.52

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.21
SG&A to Revenue	0.19